key: cord-0017088-bj3qza6w
authors: van Wessem, Karlijn J. P.; Leenen, Luke P. H.
title: Does Liberal Prehospital and In-Hospital Tranexamic Acid Influence Outcome in Severely Injured Patients? A Prospective Cohort Study
date: 2021-04-29
journal: World J Surg
DOI: 10.1007/s00268-021-06143-y
sha: bb40585955df53fd263b56d3429218837a22e780
doc_id: 17088
cord_uid: bj3qza6w

BACKGROUND: Early hemorrhage control is important in trauma-related death prevention. Tranexamic acid (TXA) has shown to be beneficial in patients in hemorrhagic shock, although widespread adoption might result in incorrect TXA administration leading to increased morbidity and mortality. METHODS: A 7-year prospective cohort study with consecutive trauma patients admitted to a Level-1 Trauma Center ICU was performed to investigate administration of both pre- and in-hospital TXA and its relation to morbidity and mortality. Indication for prehospital and in-hospital TXA administration was (suspicion of) hemorrhagic shock, and/or systolic blood pressure (SBP) ≤ 90 mmHg. Demographics, data on physiology, resuscitation and outcomes were prospectively collected. RESULTS: Four hundred and twenty-two patients (71% males, median ISS 29, 95% blunt injuries) were included. Even though TXA patients were more severely injured with more deranged physiology, no differences in outcome were noted. Overall, thrombo-embolic complication rate was 8%. In half the patients, hemorrhagic shock was the indication for prehospital TXA, whereas 79% of in-hospital TXA was given based on suspicion of hemorrhagic shock. Thirteen percent of patients with SBP ≤ 90 mmHg in ED received no TXA at all. Based on SBP alone, 22% of prehospital TXA and 25% of in-hospital TXA were justified. CONCLUSIONS: Despite being more severely injured, TXA patients had similar outcome compared to patients without TXA. Thrombo-embolic complication rate was low despite liberal use of both prehospital and in-hospital TXA. Caution should be exercised in selecting patients for TXA, although this might be challenging based on SBP alone in patients who do not yet show signs of deranged physiology on arrival in ED. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00268-021-06143-y.

Early hemorrhage control and adequate blood product transfusion are important in trauma-related death prevention [1, 2] . Hemostatic resuscitation prevents ongoing blood loss, restores volume status and corrects coagulopathy development [3] . Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis and promotes the ability to sustain formed clots [4] . The Clinical Randomization of an Anti-fibrinolytic in Significant Hemorrhage 2 (CRASH-2) trial showed statistically significant improvement in the Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00268-021-06143-y. rates of both overall mortality and in hemorrhage-caused mortality as a result of early administration of TXA in adults who sustained an injury within 8 h and had either significant hemorrhage, hypotension or who were considered to be at risk of significant hemorrhage [5] . These results have led to widespread incorporation of TXA in damage control resuscitation with low thresholds to administer TXA, including in prehospital settings. However, concerns have been raised that indiscriminate widespread adoption might result in TXA administration in the wrong patients, leading to increased morbidity and mortality [6] [7] [8] [9] . Data in the literature have been contradicting, however, with others reporting no significant differences or even decreased adverse effects [10] [11] [12] [13] [14] . At present, it remains unclear what the exact mechanism behind TXA is and how it has reduced mortality in CRASH-2 trial, since there was no reduction in packed red blood cells (PRBC) transfusion between patients who received TXA and the ones who did not [5] . Data are still lacking regarding which trauma patients might benefit most, optimal dosing and timing and potential complications in both prehospital and in-hospital setting [4, 15] .

Since most studies only focused on either prehospital or in-hospital TXA administration, we conducted a prospective population-based cohort study in polytrauma patients to investigate the indication of both pre-and in-hospital TXA administration and its relation to morbidity and mortality. We hypothesized that neither prehospital nor inhospital TXA administration was related to increased morbidity or mortality.

A 7-year prospective population-based cohort study (starting November 2013) was undertaken to investigate outcomes in severely injured patients admitted to the Intensive Care Unit (ICU) of a major (Level-1) trauma center (University Medical Center Utrecht, The Netherlands). Details of the hospital and catchment area were previously described [16] . All consecutive polytrauma patients who were admitted to the adult ICU were included. ICU admission could be either directly from the emergency department (ED) or postoperatively after urgent surgery. Patients with isolated traumatic brain injury (TBI), asphyxiation, drowning and burns were excluded, because of potential different physiologic response to severe trauma and a significantly different mortality and morbidity profile [17, 18] . Isolated injury to the brain was defined as Abbreviated Injury Score (AIS) head C 3 and AIS B 2 in other regions.

All data were prospectively collected by both authors and included demographics, shock and resuscitation parameters. Administration of both crystalloid and blood products including packed red blood cells (PRBC), fresh frozen plasma (FFP) and platelets (PLT) was documented in the first 24 h after admission. Additionally, prehospital and in-hospital administration (in ED, OR, B 8 h and B 24 h) of tranexamic acid (TXA) was recorded. Our trauma system's protocols, including prehospital protocols, recommend administering TXA within 3 h of injury for signs of the presence of impending hemorrhagic shock, hypotension (systolic blood pressure B 90 mmHg) and/or clinical suspicion of major hemorrhage. Prehospital TXA dosage was 1 g bolus, in-hospital TXA dosage was also 1 g bolus, and 1 g infusion was repeated over 8 h at discretion of the treating surgeon and/or intensivist.

Denver MOF scores [19] and ARDS Berlin criteria [20] were registered daily up until 28 days or discharge from ICU. Primary outcome was the relation between TXA administration and potentially adverse outcomes such as mortality, thrombo-embolic complications (TEC), MODS, ARDS and infections.

Secondary outcome was potential difference between pre-and in-hospital TXA administration on outcome parameters.

All statistical analyses were performed using IBM SPSS Statistics, version 25.0 (Armonk, NY, USA). Results are presented as median and interquartile range (IQR). Kruskal-Wallis was used to test continuous variables for equality between TXA and patients without TXA, whereas Chi-square or Fisher's exact test was used to test categorical data. Variables with univariate statistical significance of less than 0.10 were included in a multivariate logistic regression analysis to identify independent risk factors for TXA administration and mortality and presented as odds ratios and 95% confidence intervals. Statistical significance was set at p \ 0.05.

In this study, 422 patients (71% male) with a median age of 46 (28-62) years admitted to ICU were included. Ninetyfive percent of injuries were caused by a blunt mechanism, 50% was prehospitally intubated, and median ISS was 29 (22-36) with most severe injuries located in the brain (AIS head 3 (1-4)) and chest (AIS chest 3 (2-4)). One hundred and three patients (24%) underwent an urgent laparotomy. Physiology, resuscitation and outcome data are presented in Table 1 . In this cohort, 79 (19%) patients died; 57 (72%) of them died of traumatic brain injury (TBI), 7 (9%) died of respiratory insufficiency, 4 (5%) due to exsanguination, 3 (4%) due to cardiac origin, 2 (3%) due to MODS, 2 (3%) due to sepsis, 1 (1%) due to ARDS and 3 (4%) due to miscellaneous causes. Sixty-six percent of patients received TXA at any point in time. During the 7-year study period, prehospital TXA administration increased (p = 0.005, Figure S1A ), whereas in-hospital TXA administration did not change over time (p = 0.14, Figure S1B ). Patients who received TXA were younger, more severely injured, with lower SBP and hemoglobin (Hb) in ED. Further, they were more acidotic and coagulopathic, underwent more often an urgent laparotomy and received more crystalloids and blood products both B 8 and B 24 h than patients who did not receive TXA. There was, however, no difference in outcome between TXA and no-TXA patients (Table 1) . There was also no difference in outcome between patients with SBP B 90 mmHg who received TXA and those who did not.

Subanalysis of patients who received prehospital TXA compared to patients who did not Forty-nine percent (n = 207) of patients received prehospital TXA, whereas 51% (n = 215) did not (Fig. 1) . Median time from call to dispatch to ED (prehospital time) was 1:00 h (0:55-1:08), so all prehospital TXA was administered within 1 h after injury. Patients who received prehospital TXA were younger, slightly more severely injured and more often prehospitally intubated. Further, prehospital TXA patients had lower Hb and were more acidotic in ED with higher PaCO2. They received more crystalloids and PRBC B 8 and B 24 h. There was no difference in outcome ( Table 2 ). All four patients (50% had SBP B 90 mmHg) who later died of hemorrhage did not receive prehospital TXA. However, they all did receive TXA in OR.

Two hundred and seventy-six (65%) patients received inhospital TXA, whereas 146 did not (Fig. 1) . Seventy-four percent had already received prehospital TXA. Patients who received in-hospital TXA were younger, more severely injured with lower SBP and Hb, more acidotic and coagulopathic in ED than patients who did not receive inhospital TXA. Further, they underwent more often urgent laparotomies and received more crystalloids and blood products B 8 and B 24 h. Again, there was no difference in outcome (Table 3) .

Median time to TXA was 1:02 h (0:58-1:20). The time frame within TXA was administered is shown in Fig. 2 . Ninety-three percent of patients who had TXA received it early (\ 3 h) after injury. There was no difference in outcome in patients who had early TXA compared to late TXA (C 3 h) (Table S1 ).

There was no significant difference in TXA dosage in TXA patients who received early TXA compared to late TXA (1 g (1-2) vs. 1 g (1-1), p = 0.16). There was also no difference in TXA dosage between patients who developed TEC and those who did not (1 g (1-2) vs. 1 g (1-1), respectively, p = 0.20). (Table 4 ).

In multivariate analysis, age, hemoglobin, PaCO2 and pH in ED were independent predictors for TXA administration. Age, ISS and base deficit in ED were independent predictors for mortality. TXA, however, was not related to death (Tables 5, 6 ).

In this cohort of polytrauma patients, there was no difference in outcome between patients who received TXA and those who did not, even though TXA patients were more severely injured with more deranged physiology.

Subanalysis of prehospital and in-hospital TXA administration also revealed no difference in outcome. Based on systolic blood pressure alone (SBP B 90 mmHg), large numbers of unjustified prehospital and in-hospital TXA administration were found. However, these large numbers could be slightly overestimated since no data on prehospital SBP were collected and the first collected SBP for this study was in ED. It is possible that prehospital SBP could have been higher and decreased during transport. Moreover, since the original inclusion to administer TXA was a rather vague and subjective description of ''signs of the presence of impending hemorrhagic shock and/or clinical suspicion of major hemorrhage,'' in this study SBP B 90 mmHg was used as most objective measurement of hemorrhagic shock to be able to calculate whether TXA administration was justified. This strict inclusion of SBP B 90 mmHg might label TXA as ''unjustified'' in some patients with normal SBP even though they were in imminent shock. Especially in prehospital settings, it could be difficult to diagnose early signs of hemorrhagic shock, and a ''better safe than sorry'' attitude is often adopted. Another reason for TXA administration in patients without hypotension might be explained by a previously described phenomenon in which severely injured patients in smaller service areas with short transport times do not have deranged physiologic parameters on arrival in ED. These patients did not have the time to deteriorate, because they were in the hospital before blood pressure, BD and hemoglobin will change distinctly [21, 22] .

This liberal approach of prehospital TXA administration even increased over time during the 7-year study and has recently also been described by Kheirbek et al. Despite large numbers of unjustified TXA use, they also did not demonstrate difference in TEC [23] .

In addition to the rationale of unjustified TXA administration, it is also intriguing why patients with signs of shock did not receive TXA. A few of these patients had shock based on other causes than hemorrhage such as neurogenic shock based on high spinal cord lesion. Four patients (5%) who died due to hemorrhagic shock did not receive prehospital TXA, nor in ED. They all did receive TXA in OR. It could be debated that time was so critical in these exsanguinating patients that there was simply no time Almost all patients who received TXA for the first time had it within the recommended 3 h after injury. There was no difference in dosage between patients who had early TXA and those who had late TXA nor was there any difference in outcome suggesting that both dosage and timing of TXA did not influence outcome.

Our data are in line with several other reports in the literature suggesting that TXA in a polytrauma population was not associated with increased TEC and mortality even if it was administered liberally [10] [11] [12] [13] . However, current data are in contrast to other studies that demonstrated increased mortality after TXA [6] [7] [8] [9] . A possible explanation for these seemingly contradicting data was proposed by Moore et al. suggesting that outcome after TXA might be related to fibrinolytic state of the patient with least expected benefit from TXA in patients with physiological fibrinolysis [9, 24] . In our hospital, viscoelastic tests are not routinely used in trauma. However, in a previous study thromboelastography in severely injured patients (who were part of the same cohort used in this study) showed no abnormalities [25] ; therefore, it could be assumed that the patients in this study had physiological levels of fibrinolysis. Nevertheless, there was no difference in mortality between patients who received TXA and patients who did not in this study.

Despite being more severely injured TXA patients had no difference in outcome suggesting that TXA has ameliorated outcome. This should be concluded with caution; First of all, even if only patients with SBP B 90 mmHg in ED were analyzed, there was no difference in morbidity and mortality between patients with and without TXA. Further, the numbers of exsanguinating patients were very low since only four patients died of hemorrhage. Additionally, it remains to be seen whether TXA is truly advantageous in settings with small service areas with short transport times and with the immediate availability of blood products and operating room to control hemorrhagic shock. In this cohort of polytrauma patients, many patients also sustained TBI (AIShead 3 (1-4) ). TBI was also the main cause of death in this population (72%). Data even suggest that prehospital TXA was often given in patients with TBI since patients who received prehospital TXA had higher AIShead, were more often prehospitally intubated and had higher PaCO2 with similar pH in ED (suggestive for prehospital hypoventilation) than patients who did not receive prehospital TXA. Several studies have reported various effects of TXA on outcome in TBI from depending on brain injury severity and timing of TXA administration [26] to no difference in outcome after prehospital TXA [27] , or even a potential harmful effect of prehospital TXA on mortality in severe TBI patients [28] . The effect of TXA on TBI in this polytrauma population was beyond the scope of this paper. Future research will focus on the effect of TXA on TBI.

A few limitations need to be acknowledged: First of all, this was a single-institution study. Further, clinicians who were treating these patients were also the researchers. Another limitation is that no details on comorbidities nor any data on prehospital and in-hospital Glasgow Coma Scale were collected.

In conclusion, TXA patients had similar outcome compared to patients without TXA despite being more severely injured. There was a liberal use of both prehospital and inhospital TXA with large numbers of patients receiving TXA without hypotension. Hemorrhagic shock was indication for prehospital TXA in only half the patients, whereas in-hospital TXA was given based on suspicion of hemorrhagic shock in the vast majority of patients. Caution should be exercised since it can be difficult to select the right patient for TXA especially in severely injured patients who do not show grossly signs of deranged physiology prehospitally or on arrival in ED yet.

Authors' contributions KW and LL have contributed to the conception and design of the study, performed acquisition of data and given final approval of the version to be submitted. KW has done the analysis and interpretation of data and drafted the article. LL has revised it critically for important intellectual content.

Funding No funds were received in connection with the presented study.

Availability of data and materials The datasets supporting the conclusions of this article are available upon reasonable request from the corresponding author.

Conflict of Interest The authors declare that they have no conflict of interest.

Ethical Approval The local ethics committee approved this prospective observational study and waived consent (reference number WAG/mb/16/026664).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.

Patterns of errors contributing to trauma mortality: lessons learned from 2,594 deaths

Epidemiology of traumatic deaths: comprehensive population-based assessment

The European guideline on management of major bleeding and coagulopathy following trauma

Tranexamic acid update in trauma

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebocontrolled trial

Do all trauma patients benefit from tranexamic acid?

Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism

Is Tranexamic acid associated with mortality or multiple organ failure following severe injury?

Tranexamic acid is associated with increased mortality in patients with physiological World J Surg fibrinolysis

Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: a double-blind, placebo-controlled, randomized clinical trial

Prehospital administration of tranexamic acid in trauma patients: A 1:1 matched comparative study from a level 1 trauma center

The incidence of venous thromboembolic events in trauma patients after tranexamic acid administration: an EAST multicenter study

Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study

PATCH-Trauma Study Investigators et al (2014) Tranexamic acid for trauma: filling the ''GAP'' in evidence

Prehospital tranexamic acid: what is the current evidence?

Demographic patterns and outcomes of patients in level-1 trauma centers in three international trauma systems

Changes in the epidemiology and prediction of multiple-organ failure after injury

Comparison of postinjury multiple-organ failure scoring systems: Denver versus Sequential Organ Failure Assessment

Early predictors of postinjury multiple organ failure

ARDS Definition Task Force et al (2012) Acute respiratory distress syndrome: the Berlin Definition

Applicability of the predictors of the historical trauma score in the present Dutch trauma population: modelling the TRISS predictors

Reduction in mortality rates of postinjury multiple organ dysfunction syndrome: a shifting paradigm?

Unjustified administration in liberal use of tranexamic acid in trauma resuscitation

Tranexamic acid in trauma: how should we use it?

Thromboelastography does not provide additional information to guide resuscitation in the severely injured

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial

Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury

Association between prehospital tranexamic acid administration and outcomes of severe traumatic brain injury